Familial recurrence studies provide strong evidence for a genetic component to the predisposition to sporadic, non-syndromic Tetralogy of Fallot (TOF), the most common cyanotic congenital heart disease (CHD) phenotype. Rare genetic variants have been identified as important contributors to the risk of CHD, but relatively small numbers of TOF cases have been studied to date. Here, we use whole exome sequencing to assess the prevalence of rare, potentially deleterious variants in candidate genes previously associated with both syndromic and non-syndromic TOF, in the largest cohort of non-syndromic TOF patients reported to date.
Introduction
Congenital heart disease (CHD) is the most common type of birth defect, affecting 8/1000 live births (1) . CHD covers a large spectrum of heterogeneous cardiovascular phenotypes that range from single, localised defects to more complex structural abnormalities. Tetralogy of Fallot (TOF) is the most common complex, cyanotic CHD with a prevalence of 1/3000 births (1, 2) . TOF is considered a malformation of the cardiac outflow tract which comprises four specific structural characteristics postnatally; a ventricular septal defect (VSD) , anterocephalad deviation of the outflow septum with resultant overriding of the aorta, variable obstruction of the right ventricular outflow tract (pulmonary stenosis) and consequent hypertrophy of the right ventricle (2, 3) . Surgical interventions during infancy mean that 85-90% of TOF patients now survive until at least 30 years of age (1, 4) . However, this is not without consequence; event-free survival is just 25% after 40 years of age (5) since resultant scar tissue from surgery and pulmonary regurgitation cause significant morbidity in adulthood (6, 7) .
The cause of TOF is elusive and no single candidate gene can be held accountable for the disease phenotype. However, the genetic status of syndromic TOF sufferers has provided valuable insights into causative genes in some patients. Approximately 20% of cases are associated with a recognised syndrome or chromosomal anomaly (2) . Most significantly, approximately 15% of TOF patients have 22q11.2 deletion syndrome, wherein the major causal gene is TBX1 (8, 9) . In approximately 80% of TOF cases which are nonsyndromic there is generally not an identifiable cause, largely due to their non-Mendelian pattern of inheritance (10) (11) (12) (13) . Accordingly, a polygenic genetic architecture has been hypothesised and genome-wide approaches have been undertaken to provide insights into the complex genetic alterations responsible for TOF and other CHDs (11, (13) (14) (15) (16) (17) (18) .
Whole exome sequencing (WES) has been used successfully to identify new CHD candidate genes (14, 17, 19, 20) . Many lines of evidence indicate a degree of phenotypic specificity of variants in particular genes. For example, the spectrum of phenotypes caused by 22q11.2 deletion or mutations in TBX1 typically involves the outflow tract and great vessels, while Down's syndrome or mutations in NKX2.5 typically cause septal defects. To date, no WES study of CHD has included substantial numbers of any homogeneous phenotype, which should a priori have the highest power to identify causal variants.
Here, we present findings from WES of the largest cohort of non-syndromic TOF patients reported to date. First, we carried out a systematic review of the literature and identified 77 genes previously associated with either syndromic or non-syndromic TOF. We subsequently performed WES in 829 TOF probands and identified rare deleterious variants in the candidate genes. We sought evidence of pathological relevance for a subset of variants in the most significantly over-represented gene, based on the variants' de novo occurrence and functional consequences in cellular models.
Methods Summary
829 TOF probands were subjected to WES and rare (minor allele frequency [MAF] ≤ 0.001 in the Exome Aggregation Consortium [ExAC] database), deleterious (combined annotation-dependent depletion [CADD] score of ≥ 20) variants in 77 TOF candidate genes were assessed. Any variants observed in 1252 reference exome samples, that were analysed using the same approach as our case data, were eliminated. Clustering analysis was used to identify genes where significantly more variants were observed than expected.
De novo variants were identified by Sanger sequencing of proband parent samples.
Immunoblotting and luciferase assays were used to assess the expression and signalling activity of selected variants. Detailed methods can be found in the Supplementary Data.
Results
The NOTCH1 locus most frequently harbours rare, deleterious variants in non-
syndromic TOF patients
We assessed the incidence of rare, deleterious variants in 77 TOF candidate genes (Supplementary Table 1 ), for 829 non-syndromic TOF cases. Any variants observed in 1252 reference exomes were removed from consideration as a potential TOF susceptibility variant (Supplementary Table 2 ). Of the 77 genes considered, NOTCH1 was the locus most frequently found to harbour a rare (ExAC MAF ≤ 0.001), deleterious (CADD ≥ 20) variant among TOF patients (table 1) , with 49 probands exhibiting 46 NOTCH1 variants, accounting for 6% of our TOF patient cohort (95% CI: 4.5% -7.8%). The second most frequent locus was DOCK6, in which 30 probands harboured 26 rare, deleterious variants (table 1) . The combined number of samples with NOTCH1 or DOCK6 variants was 76, highlighting the minimal overlap between probands with variants in these two genes (table 1). The statistical significance of these findings was assessed for each gene using clustering analysis which corrected for gene size; this confirmed a significant excess of rare, deleterious variants in six
TTC37 (P=0.016), MESP1 (P=0.024) and TBX1 (P=0.039). 126 TOF cases had a rare, deleterious variant in one or more of these genes, accounting for over 15% of our patient cohort. Clustering of variants identified in the remaining 71 candidate genes did not reach a corrected, 5% level of significance ( Supplementary Table 3 ). When relaxing our stringent filters by removal of the CADD filter ( Supplementary Table 4 ) and by increasing the MAF to ≤ 0.01 ( Supplementary Table 5 ), NOTCH1 continues to be the highest risk locus for nonsyndromic TOF, with 8% of our cohort carrying NOTCH1 variants.
NOTCH1 variants cluster within the EGF-like repeats
We mapped the distribution of the 46 NOTCH1 variants ( Supplementary Table 6 ) to the various domains of the NOTCH1 protein (figure 2). Six of the variants identified were loss-of-function (LOF; figure 2 ), including three premature stop codons (p.R448*, p.W1638* and p.Q1733*) and three single base pair deletions resulting in frameshifts and eventual premature truncation (p.G115fs*6, p.N147fs*128 and p.C1322fs*121). The three frameshift mutations were mapped to the EGF-like repeats in addition to one truncating mutant, p.R448*, whereas the remaining two truncating variants were located in the heterodimerisation domain (HD). Thus, all six LOF variants in NOTCH1 were located in the extracellular domain of the protein. Of the remaining 40 missense variants, 21 were located in amino acid residues that are conserved with Drosophila melanogaster Notch. 22 of the missense variants were novel whereas the remaining 18 were reported in the ExAC database with very low frequency (MAF<0.001). Rare, deleterious variants were located throughout the NOTCH1 protein (figure 2), mapping to both the extracellular domain and the intracellular domain. However, significantly more variants were located in the EGF-like repeats (p=0.018; Supplementary Table 7 ), after adjustment for the proportion of the protein made up by EGF-like repeats. This region represents 56% of the total protein yet harbours 74% of NOTCH1 variants. With appropriate caveat for this having been a post hoc analysis informed by our knowledge of the variant distribution, these data suggest that rare and deleterious variants in TOF are significantly enriched in the EGF-like repeats of NOTCH1. Of the intracellular domain mutants, two missense variants in the Ankyrin domain region, p.R2004L and p.A2036T, are particularly notable. R2004 is a surface exposed residue in Ankyrin domain 4 which is located in an interface region with the CSL transcription factor complex (21) and also located at an interface that binds the positive Notch regulator, Deltex (22) . A2036 is located in Ankyrin domain 5 and lies immediately adjacent to the location of a Drosophila developmental mutant N Su(42C) which is reported to reduce Notch activity (23) .
De novo variants identified in NOTCH1
We investigated the occurrence rate of de novo mutations in probands with NOTCH1 variants. Of the 49 probands in our TOF patient cohort that harboured rare, deleterious variants in NOTCH1, samples from both parents were available for thirteen probands and analysed for variant inheritance. Following Sanger sequencing, five of the thirteen NOTCH1 variants tested were identified as de novo; two of these were truncating variants, whereas the remaining three de novo variants were missense (table 2). All de novo variants identified were absent in the ExAC database and not previously reported in the literature. The remaining variants sequenced were inherited from parents and five of these were of maternal origin. Of the eight inherited variants, six were listed in ExAC with very low frequency (table 2); the remaining two variants have not been previously reported. These findings are in keeping with the results of previous WES experiments in CHD, where rare transmitted variants with strong bioinformatic support for functional impact, which are of presumed incomplete penetrance, have been uniformly encountered (14, 17, 20) .
NOTCH1 variants can affect NOTCH1 processing and signalling function
The NOTCH1 gene encodes an evolutionarily conserved transmembrane receptor that mediates cell-cell communication to govern cell fate decisions during development (24) . S1 cleavage is an important step in the maturation of the NOTCH1 receptor. During this process, the 300 kDa translation product of NOTCH1 undergoes cleavage in the Golgi by furin-like convertase to generate two polypeptides of 180 and 120 kDa (25) . To determine whether NOTCH1 variants affect S1 cleavage, we assessed the expression of three NOTCH1 variants in comparison to WT NOTCH1 by immunoblotting. The variants assessed were p.G200R, p.C607Y and p.N1875S (figure 2); p.G200R is located in a conserved residue located within a β-hairpin turn within EGF5, and p.C607Y, located in EGF16, removes a conserved disulphide bond that normally would be expected to stabilise the EGF-domain conformation. p.N1875S is located in a residue that lies in a linker region between the RAM and Ankyrin regions of the Notch intracellular domain. As expected, we observed two bands at 300 kDa (P300) and 120 kDa (P120), representing full length and cleaved NOTCH1 protein (25) ; the remaining 180 kDa product was not detectable due to the positioning of our FLAG-tag at the C-terminus (figure 3a). For WT NOTCH1, p.G200R and p.N1875S variants, we observe similar levels of both P300 and P120 (figure 3a). However, the p.C607Y variant exhibited perturbed cleavage by furin-like convertase (25) . Indeed, quantification confirmed that 5%±0.37% of NOTCH1 p.C607Y underwent cleavage in comparison to 57%±3.96% of WT NOTCH1 (P=0.0002; figure 3b ). Hence, the p.C607Y variant affects the processing of NOTCH1, whereas the receptor is processed normally in the presence of p.G200R and p.N1875S variants.
Heterodimeric NOTCH1 is membrane tethered and undergoes further cleavage by γsecretase which releases the NOTCH intracellular domain (NICD). NICD subsequently translocates to the nucleus where it interacts with transcription factor RBPJ to activate NOTCH target genes (24) . To determine whether p.G200R, p.C607Y and p.N1875S variants affect NOTCH1 canonical signalling function, we assessed NOTCH signalling through the canonical, RBPJ transcription factor-dependent pathway following stimulation with immobilised Jagged1 ligand. The variants were overexpressed in HeLa cells and NOTCH1 signalling was assessed by RBPJ luciferase activity. All three variants demonstrated reduced NOTCH signalling via RBPJ (figure 3c). The p.C607Y variant, that exhibited perturbed cleavage, significantly reduced NOTCH signalling by 47%±0.12% (P=0.008) compared to WT NOTCH1. Similarly, de novo variant p.N1875S reduced NOTCH signalling by 38%±0.13% (P=0.02). The p.G200R variant reduced NOTCH signalling by 15%±0.15%, although this finding was not significant (P=0.33) (figure 3c). No significant differences were observed between WT NOTCH1, p.G200R, p.C607Y and p.N1875S variants in the absence of JAG1 ligand. In each transfection experiment, mRNA expression of WT NOTCH1 and the three NOTCH1 variants was equal (data not shown), thus the differences in NOTCH1 signalling observed were not due to reduced mRNA expression of the variants. Hence, all three variants identified in patients that were subjected to functional testing were shown to affect canonical NOTCH1 signalling.
Discussion
TOF is the most common, severe cyanotic CHD; however, variants that could account for the high degree of genetic susceptibility inferred from familial recurrence risk studies (26) are as yet unidentified. Indeed, no single gene locus, with the exception of the 22q11 deletion, has been found to account for any significant proportion of TOF cases.
Through WES of a large cohort of sporadic, non-syndromic TOF, we show that NOTCH1 is an important susceptibility gene; 6% of patients carry heterozygous variants in NOTCH1 which, based on ExAC allele frequency, bioinformatic in silico prediction, and functional characterisation, we judged to be likely susceptibility alleles. Of the variants identified, 57%
were novel, and the remainder have previously been reported in ExAC, but with very low frequency. Six of the variants were LOF, including truncating and frame shift mutations, whereas the remaining forty variants were missense and anticipated to be pathogenic. Five out of thirteen variants tested were de novo, adding to the evidence for pathogenicity; however the remaining variants were transmitted from unaffected parents indicating incomplete penetrance. As an additional safeguard against false positive results due to systematic methodological differences between our cohort and the studies which contributed to the ExAC database, we studied a set of over 1000 reference exomes in patients free from CHD, generated and analysed in the same fashion as the case exomes, removing any variant that appeared even once in the reference exome set from consideration as a potential TOF susceptibility variant.
Previous sequencing studies of CHD have identified an association of NOTCH1 variants in left-sided cardiac malformations including bicuspid aortic valve, aortic valve stenosis, coarctation of the aorta and hypoplastic left heart syndrome (27) (28) (29) (30) . Like TOF, the causative NOTCH1 variants described for these conditions are mostly missense with a small number of LOF variants located throughout the NOTCH1 protein. In contrast, few studies, which included only a small number of patients, have implicated NOTCH1 variants in nonsyndromic TOF (27, 31) . However, there are no clear distinctions between the type and location of NOTCH1 variants identified in TOF compared to those reported in other isolated cardiovascular abnormalities. We therefore propose that genetic background and/or environmental influences may specify phenotypic expressivity.
The association of NOTCH1 with cardiac defects beyond left-sided lesions is consistent with the reported roles of NOTCH1 during heart development. Active NOTCH1 is observed in trabecular endocardium and both global and endothelial-specific knockout of Notch1 in mice results in abnormal ventricular trabeculae and abnormal cardiomyocyte patterning (32) . Relevant to TOF, Notch1 plays a role in the organisation of the outflow tract, which requires the specification of cells from both the neural crest and secondary heart field (33) . Furthermore, Notch1 is important for endocardial epithelial-to-mesenchymal transition, a process that is essential for cardiac valve formation (29, 34) . It should however be noted that all NOTCH1 variants we report are heterozygous. There are numerous reports of global and tissue specific NOTCH1 heterozygous mice that appear phenotypically normal, with no obvious cardiovascular pathologies (35, 36) . However, in a more recent study that assessed ascending aortic aneurysm, NOTCH1 +/in a predominantly 129S6 background developed aortic root dilation; and this was in contrast to NOTCH1 +/in a mixed background (37) . These findings highlight the importance of genetic background in disease expressivity and are consistent with the incomplete penetrance observed.
Mutations in key cardiac transcription factors such as NKX2.5 (38) , GATA4 (39), HAND2 (12) and GATA6 (40) have been identified in TOF cases, typically by targeted candidate gene sequencing; however these genes appear to account for just 1.7% of cases in our cohort. A Genome Wide Association Study (GWAS) of TOF cases versus controls identified risk alleles for single nucleotide polymorphisms (SNPs) in chromosomal regions 12q24 and 13q32, including the PTPN11 and GPC5 loci, respectively (13, 16) . Additionally, duplications in 1q21.1 are strongly enriched in TOF patients (11, 31) . Our findings, which in addition to NOTCH1 showed significant enrichment in five other genes (including TBX1, a well-established TOF risk gene which is principally responsible for the cardiac manifestations of 22q11 deletion) concur with previous studies regarding the marked locus heterogeneity of the condition. A possible role for NOTCH1 in non-syndromic TOF has previously been suggested by CNV analysis. A study of 34 infants with non-syndromic TOF revealed two patients with CNVs encompassing the NOTCH1 gene (41) . Additionally, a microdeletion including the NOTCH1 locus in a patient with TOF was identified in a study of CNVs in 114 TOF patients (31) . A recent study that focused primarily on families with leftsided CHD, identified family members with TOF harbouring pathogenic mutations in NOTCH1 (27) . Further indirect evidence came from a study that analysed the gene expression patterns in TOF patient right ventricles and found many genes from the NOTCH and WNT signalling pathways were significantly reduced. Interestingly, down-regulation of NOTCH signalling components was also observed in TOF patients with a 22q11.2 deletion (42), highlighting a common transcriptional signature between both syndromic and nonsyndromic TOF, initiated by different genetic events. However, the present study involves, by a substantial margin, the largest TOF cohort studied by WES to date, providing the most accurate estimate thus far of the contribution of NOTCH1 variants to TOF risk.
De novo mutations are a significant cause of early-onset genetic disorders, including CHD. Of the NOTCH1 variants identified in this study, where parents were available, five of thirteen variants were found to be de novo, all of which were novel variants not previously reported on ExAC. Furthermore, de novo variant p.N1875S was shown to have significantly reduced Jagged1-induced NOTCH signalling relative to WT NOTCH1, providing further support as to the pathogenicity of de novo variants. However, other variants were inherited from an unaffected parent, confirming the role of incompletely penetrant variants observed for other CHD genes and phenotypes (17, 20) . identified in two patients with left ventricular outflow tract malformations, also perturbed S1 cleavage by similar levels. In both cases, this led to a 50% reduction in RBPJ luciferase activity (44) . The mechanism by which such variants alter S1 cleavage requires further research.
Autosomal dominant germ-line mutations in the NOTCH1 gene are one of the causes of Adams-Oliver syndrome (AOS) which is chiefly characterised by aplasia cutis congenita and terminal transverse limb defects. In addition, around half of patients exhibit congenital cardiac anomalies, including atrial septal defect (ASD), VSD, aortic valve stenosis, pulmonary valve stenosis and TOF (51, 52) . AOS is an extremely rare syndrome, with a prevalence of approximately 1 in 225,000 (52) . No patient in our cohort had diagnostic features of AOS. Like TOF, the causative NOTCH1 variants described for AOS are both missense and LOF variants that are not confined to one specific protein domain; however, the majority of reported variants are similarly located in the EGF-like repeats (51, 52) . There are no clear distinctions between the NOTCH1 variants we have identified in TOF versus those that cause AOS, though no previously described AOS variant was present in our cases. The extra-cardiac features of AOS have been suggested to be due to early embryonic vascular abnormalities (53) ; this raises the possibility that AOS, TOF and other cardiac anomalies that occur due to mutations in NOTCH1 may be a spectrum of disorders.
Other examples of syndromic genes that can cause isolated CHD, including TOF, are PTPN11 (Noonan's syndrome), (13, 54) , TBX5 (Holt-Oram syndrome) (55) and JAG1 (Alagille syndrome) (56) . Determining the role of genetic background, environmental context and the specific NOTCH1 variants in determining the severity of the cardiac phenotype and the occurrence of extra-cardiac malformations requires further research.
The second gene identified in the current study, DOCK6, has also been identified as a causative gene in AOS, responsible for an autosomal-recessive form, often associated with impaired vascular function (57, 58) . The DOCK6 gene encodes a highly conserved member of the Dedicator of Cytokinesis family and functions as an atypical nucleotide exchange factor. Specifically, DOCK6 plays a role in the remodelling of the actin cytoskeleton by activating two members of the Rho GTPase family, CDC42 and RAC1 (59) .
Studies thus far have demonstrated a role for DOCK6 in axonal extension and branching during neuronal development (59, 60) . Presently, there is no simple functional read out for DOCK6, precluding detailed characterisation of the variants we discovered in cellular systems. However, investigations into a possible role for DOCK6 in cardiovascular development would be of interest.
In addition to NOTCH1 and DOCK6, significant clustering of rare, deleterious variants was also observed in an additional four genes, MYOM2, TTC37, MESP1 and TBX1, accounting for approximately 4% of TOF cases in our cohort. These findings emphasise the genetic heterogeneity that may ultimately lead to a TOF phenotype. The MYOM2 gene encodes Myomesin-2, a well characterised sarcomeric protein that is a major structural MESP1 encodes for Mesoderm posterior basic helix-loop-helix transcription factor 1, which plays an essential role during heart development. Mesp1 is expressed in cardiac progenitors and participates in the timely specification of the cardiac lineage in mouse cardiac development (64) (65) (66) . Investigations in mice suggest Mesp1 may act upstream of critical cardiac transcription factors including Hand2, Gata4, Nkx2.5 and Tbx20 (64, 65) . In a previous study, six rare, non-synonymous MESP1 variants were identified in 647 patients with congenital conotruncal and related heart defects, including TOF (67) . Finally, TBX1
encodes T-box transcription factor 1 which has important roles during development including the migration of cardiac neural crest cells and cellular proliferation in the second heart field (68) . TBX1 is also responsible for the cardiac abnormalities associated with the 22q.11.2 deletion syndrome (69) , which is the major contributor to the incidence of TOF (8, 9) . In agreement with Griffin et al (2010) , the present study confirms that rare, deleterious TBX1 variants contribute to a small proportion of non-syndromic TOF cases (70) .
In summary, among the genes that have been implicated in TOF thus far, our large study indicates that of the 77 TOF candidate genes tested, no gene accounts for more than 8% (upper 95% binomial confidence interval) of non-syndromic TOF. Among these genes NOTCH1 is the most commonly involved. The two most commonly involved genes (NOTCH1 and DOCK6) are also both involved in the predisposition to AOS, suggesting further investigation of common pathways between these conditions may be fruitful. Some mutations in NOTCH1 that are associated with TOF were de novo, but others were present in apparently asymptomatic individuals, indicating incomplete penetrance. Such incomplete penetrance has been prominently observed, for example, in Mendelian aortopathies, emphasising the importance of genetic background in structural cardiac and vascular diseases. Detailed phenotypic studies of mutation carriers who do not have overt CHD using advanced imaging may be of interest to delineate quantitative phenotypes potentially relevant to CHD. 
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